Page 9 - OHKF_Biotech_EN
P. 9

and link certain government fundings with universities’ performance   the Loop to instigate reforms. We recommend that the Shenzhen
            under the framework, thereby incentivising university researchers to   Municipal Government first seek the approval of the Central
            engage in knowledge transfer activities; 2) universities in Hong Kong   Government on implementing comprehensive authorisation in the
            should revise regulations on researchers engaging in outside work   Loop, and that the Hong Kong and Shenzhen governments also
            to increase hours available for knowledge transfer activities so as   jointly seek the authorisation of various Ministries and Departments
            to facilitate their engagement in cross-border activities; and 3)   to implement pilot policies in biotech reform. Meanwhile, appropriate
            universities should also provide courses geared towards the training   fault tolerance mechanisms and effective incentivising measures
            of multi-skilled talent with backgrounds in biotech and business,   should be put in place in the Loop to ensure the successful
            with a view to closing the talent gap on business operations and   implementation of comprehensive authorisation. A biotech expert
            investment in the biotech industry.                         advisory committee consisting of top-notch professionals within
                                                                        China and from overseas should be established in the Loop to put
                                                                        forward specific recommendations on the development of the
              Recommendation 5   Strengthening
              coordination and seeking comprehensive                    biotech industry, as well as exploring issues like ethics review
              authorisation                                             procedures, mutual recognition of results in clinical trials, drug
                                                                        application review and approval procedures, etc.
            Despite the high-level framework provided by the Office of the
            Leading Group for the Development of the GBA, policy oversight   Recommendation 6    Bridging the two cities’
            and coordination between the two cities are still insufficient,   systems and regimes
            marked by the absence of a coordinated development plan for
            “one zone, two parks”. We therefore recommend the           The competent Central authorities should work on smoothing out
            establishment of a relevant body, designated channel or platform   differences in the two cities’ systems and regimes. In terms of market
            under the Leading Group framework to provide oversight and   access, Hong Kong does not place any restrictions on Mainland
            coordination of the Loop’s development under the “one zone, two   enterprises, but the Mainland subjects Hong Kong enterprises to
            parks” arrangement, and expedite the formulation of a HK-SZ   restrictions by means of a negative list. We therefore recommend that
            “Joint Policy Package” that encompasses a range of issues like   the National Development and Reform Commission and the Ministry
            attraction of top-notch talent, movement of researchers,    of Commerce ease restrictions on the negative list in relation to
            management of organisations, capital flow and opening up of   foreign capital accessing the stem cell, genetic diagnostics, and
            the network, etc.                                           therapy markets, and allow direct entry to the Mainland market by
                                                                        Hong Kong biotech enterprises that are registered in the Loop and
            In order to create a pilot and demonstration area for HK-SZ   have Hong Kong permanent residents of Chinese nationality serving
            collaboration in biotech, more autonomy should be conferred to
                                                                        as a legal person or major shareholder, and treat said enterprises as if
                                                                        they were domestically-owned enterprises.
                                                                                                                                      7
   4   5   6   7   8   9   10   11   12   13   14